WNAM Monitoring: President Shavkat Mirziyoyev chaired a meeting on regulating the pharmaceutical industry and providing the population with high-quality and safe medicines.
The world is experiencing growth in the pharmaceutical industry, and new types and compositions of medicines are appearing. This necessitates constant monitoring of their quality, identification, and analysis of side effects.
On January 23, the President signed the Decree “On additional measures to regulate the pharmaceutical industry”.
Thus, organizations that produce and sell medicines and medical products are responsible for ensuring the quality and safety of their products. Special rules of state control will be established for them.
A system is being created to promptly identify and respond to threats associated with the use of medicines. For this purpose, the Good Pharmacovigilance Practices (GVP) standard will be introduced, and an electronic database on side effects of drugs will be created in the Ministry of Health. Prompt information about such actions will be provided to medical workers and the public.
Customs and free warehouses where medicines and medical supplies are stored will be gradually brought into compliance with the requirements of the Good Storage Practice (GSP) rules. The Center for Good Practices under the Pharmaceutical Industry Development Agency is being reorganized into a government agency.
Advertising of drugs and dietary supplements on television and radio channels will be allowed only based on the conclusion of a special council to be established under the Ministry of Health.
The Head of state, noting the importance of regulating the industry for public health and the economy, gave additional instructions on organizing the effective implementation of the decree.
